To obtain the subject new compound, a specific steroid with a 17- spiromethylene lactone group or the like, with low affinity for a progesterone receptor and slight side effects, and usable as a contraceptive, or in treating menstrual disorders and hormone-dependent tumors.

This compound is a new steroid with a 17-spiromethylene lactone group of formula I [R1 is O, (H, H) or (H, OR) (R is H, a 1-6C alkyl or 1-6C acryl); R2 is H, a halogen-substituted 1-6C alkyl, halogen-substituted 2-6C alkenyl, halogen or the like; R2' is H, or joined together with R2 into a 1-6C alkylidene; R3 is H, or joined together with R2' into a bond; R4 is a 1-6C alkyl; R5 and R6 are such that one of them is H, the other being H or a 1-6C alkyl; X is (CH2)n ((n) is 2 or 3), (CnH2n-2) or the like; Y is O or (H, OH); dashed line is an arbitrary bond, with a proviso that at least one of 4-5 bond, 5-10 bond and 9-10 bond being a double bond]. The compound is obtained by cyclization reaction of a compound of formula II (L is an eliminable group; (n) is 2 or 3; Q is H, a 1-6C alkyl or the like; R1' is a portion of R).